Cyclopentanohydrophenanthrene Ring System Patents (Class 514/26)
-
Patent number: 9494589Abstract: A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the ? subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside.Type: GrantFiled: April 29, 2015Date of Patent: November 15, 2016Assignee: Phoenix Biotechnology, Inc.Inventors: Otis C. Addington, Peiying Yang, Robert A. Newman
-
Patent number: 9486467Abstract: The present invention includes methods for treating or preventing a cancer in a mammal comprising administering to the mammal a therapeutically effective amount of a macrolide antibiotic such as tylosin, erythromycin, oleandomycin, spiramycin, and pharmaceutically acceptable salts and derivatives thereof.Type: GrantFiled: June 12, 2007Date of Patent: November 8, 2016Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD.Inventor: Rina Rosin-Arbesfeld
-
Patent number: 9480755Abstract: The present invention relates to pharmaceutical compositions comprising dapagliflozin and cyclodextrin, preferably (2-hydroxy)propyl-b-cyclodextrin or ?-cyclodextrin, preferably as inclusion complex. The invention further relates to a process for producing said pharmaceutical compositions. Finally, the invention relates to the use of cyclodextrin for producing dapagliflozin-containing dosage forms and to methods of purification of dapagliflozin.Type: GrantFiled: June 1, 2012Date of Patent: November 1, 2016Assignee: ratiopharm GmbHInventors: István Puskas, Lajos Szente
-
Patent number: 9446147Abstract: A sugar-anchor polymer and methods of making and using the same to stabilize a lipid membrane. The sugar-anchor polymer includes a sugar covalently bound to a first anchor and a second anchor wherein the covalent bonds are selected from the group consisting essentially of an oxime bond, a hydrazone bond, an acylhydrazide bond, an aminothioacetal bond, an acetal bond, a thioacetal bond, a dithioacetal bond, a thioether bond and combinations thereof. The method includes reacting a sugar having at least two nucleophilic moieties with at least two anchors, each anchor having at least one electrophilic moiety, to form the polymer. Alternatively, the method includes reacting a sugar having at least two electrophilic moieties with at least two anchors, each anchor having at least one nucleophilic moiety, to form the polymer. The anchors may be lipids or peptides. The sugar-anchor polymers stabilize lipid membranes against serum proteins, dehydration, and cryopreservation.Type: GrantFiled: February 24, 2012Date of Patent: September 20, 2016Assignee: The Ohio State UniversityInventor: Dennis Bong
-
Patent number: 9399775Abstract: The present invention provides RNAi agents, e.g., double stranded RNAi agents, that target the transthyretin (TTR) gene and methods of using such RNAi agents for treating or preventing TTR-associated diseases.Type: GrantFiled: November 16, 2012Date of Patent: July 26, 2016Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Kallanthottathil G. Rajeev, Tracy Zimmermann, Muthiah Manoharan, Martin Maier, Satyanarayana Kuchimanchi, Klaus Charisse
-
Patent number: 9320743Abstract: Disclosed is the use of 5?-androstane-3?,5,6?-triol in preparing neuroprotective drugs. The compound has significant protective effect against neuron injuries caused by cerebral ischemia, spinal cord ischemia or hypoxia and has no obvious toxic reaction within effective dose thereof.Type: GrantFiled: July 15, 2014Date of Patent: April 26, 2016Assignee: GUANGZHOU CELLPROTEK PHARMACEUTICAL LTD.Inventors: Guangmei Yan, Haiyan Hu, Tiandong Leng, Hanfei Sang, Jingxia Zhang, Pengxin Qiu, Shujia Zhou, Jiesi Chen, Xiuhua You
-
Patent number: 9314492Abstract: The present invention relates to a composition for preventing or treating cancer, which contains, as an active ingredient, a Panax ginseng cambium-derived cell line including wild ginseng or ginseng; a lysate thereof; an extract thereof; or a culture medium thereof, which are derived from a natural and have minimized side effects compared to the conventional therapeutic drugs, and thus are safe for the human body. Also, they are involved directly in the growth of cancer to induce cancer cell death effectively, and show anticancer activity of inhibiting or reducing the formation of tumor or the growth of tumor.Type: GrantFiled: November 6, 2009Date of Patent: April 19, 2016Assignees: UNHWA CORPORATIONInventors: Young Woo Jin, Eun Kyong Lee
-
Patent number: 9301970Abstract: Disclosed are methods and materials for treating or preventing complications due to traumatic injuries using estrogen or derivatives thereof.Type: GrantFiled: February 16, 2010Date of Patent: April 5, 2016Assignee: The UAB Research FoundationInventors: Irshad H. Chaudry, William J. Hubbard, Zheng Feng Ba
-
Patent number: 9248158Abstract: In one embodiment, the present application provides an herbal supplement and method for treating bloating, constipation and/or weight gain in a human subject comprising orally administering to a subject in need thereof an effective amount of the herbal supplement comprising a red quebracho extract. In other embodiments, the supplement may additionally include a triterpenoid saponin, an anti-spasmodic agent, or both.Type: GrantFiled: November 5, 2013Date of Patent: February 2, 2016Assignee: KBS RESEARCH, LLCInventors: Kenneth Brown, Brandi M. Scott
-
Patent number: 9173851Abstract: An enteric-coated bead dosage form of cysteamine, and related methods of manufacture and use, are disclosed.Type: GrantFiled: June 26, 2015Date of Patent: November 3, 2015Assignee: RAPTOR PHARMACEUTICALS INC.Inventors: Kathlene Powell, Ramesh Muttavarapu
-
Patent number: 9161985Abstract: A 5?-androstane-3?,5,6?-triol injection and its preparation are disclosed. The injection uses hydroxypropyl-?-cyclodextrin as a solubilizing agent and the active ingredient is present at a weight ratio of 1-20:40-500 to the hydroxypropyl-?-cyclodextrin. The injection may also comprise, by weight, 1-100 parts of at least one isotonic adjusting agent, 0-200 parts of at least one freeze drying filler, and 0-2000 parts of at least one solvent. The preparation method comprises dissolving hydroxypropyl-?-cyclodextrin solution, 5?-androstane-3?,5,6?-triol and at least one additional soluble excipient in water for injection in sequence to obtain a raw injection solution, and subjecting the raw injection solution to decolorization, depyrogenation, filtration and sterilization to obtain the injection, Drying the filtrate yields a solid for injection.Type: GrantFiled: July 8, 2011Date of Patent: October 20, 2015Assignee: Guangzhou Cellprotek Pharmaceutical Ltd.Inventors: Guangmei Yan, Halyan Hu, Jingxia Zhang, Pengxin Qiu, Ling Li, Ning Tian
-
Patent number: 9114102Abstract: Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2 or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering peliomycin and other compounds described herein.Type: GrantFiled: November 5, 2008Date of Patent: August 25, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Curtis J. Henrich, Heidi R. Bokesch, Susan E. Bates, Robert W. Robey, Suneet Shukla, Suresh V. Ambudkar, Michael C. Dean, James B. McMahon
-
Patent number: 9109003Abstract: The present invention provides an extraction method for the leaves of Ilex kudingcha C. J. Tseng, and the total saponins from I. kudingcha leaves extracted by using this method, and use of the total saponins in preparing a drug for reducing cholesterol and blood lipids and anti-atherosclerosis. The extraction method comprises the following steps: subjecting I. kudingcha leaves to refluxing extraction with ethanol aqueous solution to obtain an extracted solution; filtering the extracted solution and removing ethanol, and then separating and purifying the solution using a macroporous resin column.Type: GrantFiled: December 21, 2011Date of Patent: August 18, 2015Assignee: Peking UniversityInventors: Pengfei Tu, Tongmei Zhang, Jiao Zheng, Yong Jiang, Haiyan Zhou, Li Tang, Zhizhong Ma
-
Patent number: 9101575Abstract: Agonists of vascular endothelial sphingosine-1-phosphate receptors are described. Compounds such as FTY720 can be phosphorylated by sphingosine kinase-2 into the phosphorylated forms which serve as sphingosine-1-phosphate receptor agonists. The vascular endothelial sphingosine-1-phosphate receptor agonists are employed in methods of treating a mammal for vascular permeability disorders and unwanted vascular endothelial cell apoptosis, and for the growth of new blood vessels. The sphingosine-1-phosphate receptor agonists can be used for the manufacture of a medicament for treating vascular permeability disorders and unwanted vascular endothelial cell apoptosis, and for the growth of new blood vessels.Type: GrantFiled: September 30, 2010Date of Patent: August 11, 2015Assignee: THE UNIVERSITY OF CONNECTICUTInventors: Timothy Hla, Teresa Sanchez, Kevin Patrick Claffey, Ji-Hye Paik
-
Publication number: 20150132409Abstract: Agents and devices for affecting nerve function are described. In some variations, a combination of agents, e.g., a cardiac glycoside, an ACE inhibitor, and an NSAID are delivered to affect nerve function. The agent may be delivered locally in a site-specific manner to a targeted nerve or portion of a nerve. For example, the agent may be delivered locally to the renal nerves to impair their function and treat hypertension. One variation of a delivery device includes one or more needle housings supported by a balloon. A delivery needle is slidably disposed within a needle lumen of each needle housing.Type: ApplicationFiled: May 7, 2013Publication date: May 14, 2015Inventors: Emily A. Stein, Christina D. Swanson, Michael A. Evans, Kondapavulur T. Venkateswara-Rao
-
Patent number: 9029414Abstract: The present invention provides therapeutically active compounds and compositions as receptor antagonists and methods of use thereof. In one aspect, the compounds are useful in modulating pain, inflammation and acute phase reactions by inhibiting the PGE2 receptors including PGE2 EP1, EP2 and EP4 receptors.Type: GrantFiled: September 19, 2009Date of Patent: May 12, 2015Assignee: Biotechnology Research CorporationInventors: Nancy Yuk-Yu Ip, Fanny Chui-Fun Ip, Yueqing Hu
-
Patent number: 9029334Abstract: Disclosed is a pharmaceutical composition for the prevention or treatment of metabolic bone diseases, comprising a spinasterol glucoside derivative, or an optical isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof. The pharmaceutical composition is effectively useful for preventing or treating metabolic bone diseases.Type: GrantFiled: May 13, 2013Date of Patent: May 12, 2015Assignee: Lifetree Biotech Co., Ltd.Inventors: Chun-Soo Na, Cheol Yi Hong, Hee Kyong Kim, Sun-Young Yoon, Jin-Beom Kim, Hyun-Jung Roh, Hye-Ji Noh, Na-Na Um, Jiyoung Kim, Tae Hoon Lee
-
Publication number: 20150126464Abstract: A primary objective is to provide a drug for radical cure and a therapeutic method for diseases associated with axonal dysfunction (for example, Alzheimer's disease, dementia, Parkinson's disease, spinal cord injury, or brain contusion) based on the pathogenic mechanism thereof. Provided is a compound having a stimulating activity on 1,25D3-MARRS or a pharmaceutically acceptable salt thereof. Also provided is a technical idea relating to a pharmaceutical composition for disease treatment comprising a therapeutically effective amount thereof, a production method, a method for preventing or treating a disease, and a kit.Type: ApplicationFiled: July 24, 2013Publication date: May 7, 2015Inventor: Chihiro Tohda
-
Publication number: 20150126463Abstract: The present invention relates to the use of a compound comprising plant based saponins for regulating and balancing gut microflora in a subject. The present invention also relates to the use of a compound comprising plant based saponins for exerting anti-cancer effects by regulating and balancing the gut microbial ecosystem for a subject.Type: ApplicationFiled: May 29, 2014Publication date: May 7, 2015Inventors: Wen Luan Wendy Hsiao, Lei Chen
-
Patent number: 9018175Abstract: The compounds of Formula (1), in which A, R1, R2, R3 and R5 have the meanings as given in the description, are novel effective inhibitors of type 4 and 5 phosphodiesterase.Type: GrantFiled: December 15, 2010Date of Patent: April 28, 2015Assignee: Takeda GmbHInventors: Dieter Flockerzi, Thomas Stengel, Alexander Mann, Harald Ohmer, Ulrich Kautz, Steffen Weinbrenner, Stefan Fischer, Christof Zitt, Armin Hatzelmann, Torsten Dunkern, Christian Hesslinger, Thomas Maier, Hermann Tenor, Clemens Braun, Raimund Külzer, Degenhard Marx
-
Publication number: 20150111843Abstract: Disclosed herein are novel oxetane derivatives of avicin D, including compounds of the formula (I), wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising these derivative compounds. Methods and intermediates useful for making the derivatives, and methods of using the derivatives and compositions thereof, including for the treatment of cancer, are also provided.Type: ApplicationFiled: February 22, 2013Publication date: April 23, 2015Inventors: Valsala HARIDAS, Jordan GUTTERMAN, David L. PARKER
-
Publication number: 20150099712Abstract: A method for treating cancer by using an agent which is capable of inhibiting the functionality of the MCM complex, a heterohexameric ring formed from six subunits, in the process of DNA replication and a method of screening for such agents by detecting the locations and functions of the MCM subunits, such as hMcm2 and hMcm6, in cells treated with candidate compounds.Type: ApplicationFiled: May 9, 2013Publication date: April 9, 2015Inventors: Chun Liang, Zhihong Jiang, Ziyi Wang, Zhiling Yu, Jingrong Wang, Liping Bai
-
Publication number: 20150099711Abstract: A method for modifying a quality of a fruit includes cutting a live stem attached to a live fruit at a cut distance from the fruit, producing a cut end of the stem, contacting only the cut end of the stem with a solution comprising at least one mobile and quality-modifying food ingredient while protecting the fruit from contact with the solution, and keeping the cut end of the stem in contact with the solution for an incubation time sufficient to allow absorption and transport of the food ingredient into the fruit, the food ingredient conferring a modified quality upon the fruit. A system for practicing the method and an edible raw plant product produced by the method are also disclosed.Type: ApplicationFiled: April 7, 2014Publication date: April 9, 2015Applicant: Nightshade, LLCInventors: Caius D. Rommens, Heather M. Holloway, Roy D. Holloway
-
Publication number: 20150093455Abstract: The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient, such as, for example, HIV infection, various degenerative diseases, and acute or chronic skin ailments. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and proliferation of stem cells.Type: ApplicationFiled: June 24, 2014Publication date: April 2, 2015Inventors: Calvin Bruce HARLEY, Allison C. CHIN, Tsutomu AKAMA, Nancy Yuk-Yu IP, Yung-Hou WONG, David M. MILLER-MARTINI
-
Patent number: 8987217Abstract: Methods of treating a fungal infection in a subject, the method comprising administering to the subject a modified saponin.Type: GrantFiled: January 11, 2011Date of Patent: March 24, 2015Assignees: The General Hospital Corporation, The Broad Institute, Inc., Massachusetts Institute of TechnologyInventors: Eleftherios Mylonakis, Edward Holson, Frederick M. Ausubel
-
Publication number: 20150080327Abstract: A targeted osmotic lysis (TOL) of tumor cells that over-express voltage-gated sodium channels (VGSCs) has been developed that uses a combined therapy of a drug that blocks sodium, potassium-adenosine triphosphatase (Na+, K+-ATPase) that is then followed by an activation of VGSCs, for example, by electrical or pharmacological stimulation. Activation of VGSCs conducts sodium into the cancer cells in much greater amounts than non-cancer cells. Water follows this sodium gradient into the cancer cells, causing swelling and lysis. Because non-cancerous cells do not over-express VGSCs, less sodium and less water will enter the cells, and the non-cancerous cells will not lyse. This method is applicable to all cells that over-express VGSCs, including, but not limited to, highly invasive breast cancer, prostate cancer, small cell lung cancer, non-small cell lung carcinoma, lymphoma, mesothelioma, neuroblastoma, and cervical cancer.Type: ApplicationFiled: November 25, 2014Publication date: March 19, 2015Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Dennis J. Paul, Harry J. Gould
-
Publication number: 20150079029Abstract: The present invention relates to a method of inhibiting angiogenesis in a biological system. The method includes administering to the biological system an effective amount of a steroid saponin.Type: ApplicationFiled: August 27, 2014Publication date: March 19, 2015Inventors: Michael John Story, Kenneth Michael Wayte
-
Publication number: 20150072012Abstract: A highly bioavailable, water soluble, sustained release nanoformulation comprising a hydrophobic plant derived compound(s) in an emulsifier phase, and aqueous phase. The formulation provides sustained release of the hydrophobic plant derived compound(s) over a 24 hr time period. A process for preparation of the water soluble nanoformulation is described.Type: ApplicationFiled: November 13, 2014Publication date: March 12, 2015Inventors: Ravichandran SRIPATHY, Venkata Narasimha Siva Rama Raju MANDAPATI, Gopaal AJAY, Nirvanashetty SOMASHEKARA, Ramchand Nanappan CHANIYILPARAMPU, Rama Raju GOKARAJU, Ganga Raju GOKARAJU, Kiran BHUPATHIRAJU, Dwarakanath ANJANA
-
Publication number: 20150065440Abstract: The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.Type: ApplicationFiled: September 5, 2014Publication date: March 5, 2015Inventors: Vito Ferro, Tomislav Karoli, Ligong Liu, Paul Newton Handley, Kenneth David Johnstone, Norbert Wimmer, Edward Timothy Hammond
-
Patent number: 8962574Abstract: A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has at least one risk factor for major bleeding events, the method comprising administering to the patient 110 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 10, 2009Date of Patent: February 24, 2015Assignee: Boehringer Ingelheim International GmbHInventor: Paul Anthony Reilly
-
Publication number: 20150050367Abstract: Provided herein are timosaponin compounds of Formula I, II, III, I?, II? and III?, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are uses of said timosaponin compounds for preparing medicament for the treatment of diseases associated with beta-amyloid in hosts or subjects in need thereof.Type: ApplicationFiled: April 2, 2013Publication date: February 19, 2015Inventors: Chiming Che, Laiking Sy, Chunnam Lok
-
Publication number: 20150024039Abstract: This invention relates to methods of enhancing the permeability of blood vessels to therapeutic agents.Type: ApplicationFiled: October 3, 2014Publication date: January 22, 2015Inventors: Dariush Davalian, Stephen Pacetti, Florian Niklas Ludwig, Syed Faiyaz Ahmed Hossainy, Irina Astafieva, Kimchi Tran
-
Publication number: 20150023915Abstract: The present invention relates to combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include MEK inhibitors combination with cardiac glycosides.Type: ApplicationFiled: May 16, 2014Publication date: January 22, 2015Applicant: The Board of Regents of the University of Texas SystemInventors: Sean MORRISON, Ugur ESKIOCAK
-
Patent number: 8921320Abstract: A targeted osmotic lysis (TOL) of tumor cells that over-express voltage-gated sodium channels (VGSCs) has been developed that uses a combined therapy of a drug that blocks sodium, potassium-adenosine triphosphatase (Na+, K+-ATPase) that is then followed by an activation of VGSCs, for example, by electrical or pharmacological stimulation. Activation of VGSCs conducts sodium into the cancer cells in much greater amounts than non-cancer cells. Water follows this sodium gradient into the cancer cells, causing swelling and lysis. Because non-cancerous cells do not over-express VGSCs, less sodium and less water will enter the cells, and the non-cancerous cells will not lyse. This method is applicable to all cells that over-express VGSCs, including, but not limited to, highly invasive breast cancer, prostate cancer, small cell lung cancer, non-small cell lung carcinoma, lymphoma, mesothelioma, neuroblastoma, and cervical cancer.Type: GrantFiled: July 19, 2012Date of Patent: December 30, 2014Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Dennis J. Paul, Harry J. Gould
-
Publication number: 20140378399Abstract: The present disclosure relates to a novel vascular leakage inhibitor. The novel vascular leakage inhibitor of the present invention inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by VEGF, and enhances the cortical actin ring structure, thereby inhibiting vascular leakage. Accordingly, the vascular leakage inhibitor of the present invention can prevent or treat various diseases caused by vascular leakage. Since the vascular leakage inhibitor of the present invention is synthesized from commercially available or easily synthesizable pregnenolones, it has remarkably superior feasibility of commercial synthesis.Type: ApplicationFiled: December 28, 2012Publication date: December 25, 2014Inventors: Young-Gune Kwon, Young-Ger Suh
-
Publication number: 20140370122Abstract: The present invention relates to a method of inhibiting growth of a cancerous cell. The method includes the step of exposing the cancerous cell to an anti-cancer therapy and an effective amount of a steroid saponin.Type: ApplicationFiled: September 3, 2014Publication date: December 18, 2014Inventors: Michael John Story, Kenneth Michael Wayte
-
Patent number: 8906867Abstract: The production method prepares a solid preparation by dissolving water-insoluble and/or water indissolvable alkaline active pharmaceutical ingredient in an acidifier-containing acid solution to obtain medicated acid liquid; homogeneously mixing alkalizer, adjuvants and the medicated acid liquid, and carrying out wet granulation. The alkalizer is a reagent to reduce the acidity of the mixture of the alkalizer and the medicated acid liquid relative to the acidity of the medicated acid liquid. The preparation method avoids the problems in mechanical pulverization, such as environmental pollution, great loss and serious security risks. This method is simply operated, has high safety coefficient and is convenient for industrialized production. Also disclosed is the solid preparation produced by the method. The solid preparation produced by the method has better dissolution performance than that produced by prior art, and has better or at least equivalent stability and content uniformity with prior art.Type: GrantFiled: December 28, 2010Date of Patent: December 9, 2014Assignees: Shanghai Zhongxi Pharmaceutical Company, Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd.Inventors: Siji Zheng, Bo Tan
-
Patent number: 8900589Abstract: The present invention relates to conjugates of therapeutically useful anthracyclines with carriers such as polyclonal and monoclonal antibodies, proteins or peptides of natural or synthetic origin; methods for their preparation, pharmaceutical composition containing them and use thereof in treating certain mammalian tumors.Type: GrantFiled: July 14, 2009Date of Patent: December 2, 2014Assignee: Genetech, Inc.Inventors: Italo Beria, Michele Caruso, John A. Flygare, Vittoria Lupi, Rita Perego, Paul Polakis, Andrew Polson, Matteo Salsa, Susan D. Spencer, Barbara Valsasina, Robert L. Cohen
-
Patent number: 8901169Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R5 and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.Type: GrantFiled: March 4, 2014Date of Patent: December 2, 2014Assignee: Theravance Biopharma R&D IP, LLCInventors: Erik Fenster, Melissa Fleury, Adam D. Hughes
-
Patent number: 8889840Abstract: The present disclosure relates to a novel vascular leakage inhibitor. The novel vascular leakage inhibitor of the present disclosure inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by VEGF, enhances the cortical actin ring structure, and improves the stability of the tight junctions (TJs) between vascular cells, thereby inhibiting vascular leakage. The vascular leakage inhibitor of the present disclosure has the activity of not only reducing vascular permeability but also recovering the integrity of damaged blood vessels. Accordingly, the vascular leakage inhibitor of the present disclosure can prevent or treat various diseases caused by vascular leakage. Since the vascular leakage inhibitor of the present disclosure is synthesized from commercially available or easily synthesizable cholesterols, it has remarkably superior feasibility of commercial synthesis.Type: GrantFiled: October 29, 2010Date of Patent: November 18, 2014Assignee: Industry-Academic Cooperation Foundation, Yonsei UniversityInventors: Young-Guen Kwon, Young-Ger Suh
-
Publication number: 20140336138Abstract: Compositions and methods for treatment of Sturge-Weber Syndrome, Klippel-Trenaunay-Weber Syndrome, Port-Wine Stains and related neurocutaneous disorders are provided. Cell lines having the somatic mutation GNAQ p.Arg183Gln amino acid substitution, which was found to be the cause of port-wine stains (prevalence 1 in 300) and Sturge-Weber syndrome are also provided. Compositions and methods for treatment of uveal melanoma are also provided herein. Methods of screening novel compounds and compositions useful in increasing RGS2 and/or RGS4 expression and function in vitro, and for treatment of Sturge-Weber Syndrome, Klippel-Trenaunay-Weber Syndrome, Port-Wine Stains and related neurocutaneous disorders are provided are also provided.Type: ApplicationFiled: May 7, 2014Publication date: November 13, 2014Applicants: The Johns Hopkins University, Kennedy Krieger Institute, Inc.Inventors: Anne M. Comi, Jonathan Pevsner, Douglas Marchuk
-
Publication number: 20140328951Abstract: The present invention provides a composition comprising ginseng extract, red ginseng extract or ginsenosides as active ingredients for the prevention, slowed progression, and treatment of macular degeneration. More specifically it provides pharmaceutical composition to improve visual function by regenerating the transport characteristics of Bruch's membrane. The present invention provides a composition comprising ginseng extract, red ginseng extract or ginsenosides as active ingredients to maintain and protect visual function in the normal population and restore deficits in visual function in the elderly population. More specifically it provides a composition to improve visual function by regenerating the transport characteristics of Bruch's membrane.Type: ApplicationFiled: October 5, 2012Publication date: November 6, 2014Applicant: GBIOMIX. CO., LTD.Inventors: Hyeon Jae Shim, Yong Dol Shin, Min Young Kang, Jae Hwan Seok, Hussain Ali, Yun Hee Lee, Cheul Mu Sim
-
Publication number: 20140301996Abstract: The inventors demonstrate that treatment of young, suckling mice with a glycolipid derived from Helicobacter pylori activates NKT cells in a CD1d-restricted fashion, and is protective against AHR in a model of allergen-induced asthma. The inventors further found that this protective effect can be transferred by NKT cells exposed to the glycolipid, and is associated with the expansion of a suppressive double-negative NKT cells and Foxp3+ TReg cells. The inventors also demonstrate herein that pre-treatment of adult mice with a glycolipid derived from Helicobacter pylori partially suppresses airway hyperreactivity and inhibits BAL inflammation in an ozone-exposure model. Accordingly, provided herein are compositions and methods for the treatment and prevention of inflammatory diseases, such as asthma or autoimmune diseases, in a subject in need thereof.Type: ApplicationFiled: May 24, 2011Publication date: October 9, 2014Applicants: UNIVERSITY OF BIRMINGHAM, CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Dale T. Umetsu, Rosemarie Helena De Kruyff, Ya-Jen Chang, Petr Illarionov
-
Publication number: 20140296170Abstract: Disclosed is a pharmaceutical composition for the prevention or treatment of metabolic bone diseases, comprising a spinasterol glucoside derivative, or an optical isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof. The pharmaceutical composition is effectively useful for preventing or treating metabolic bone diseases.Type: ApplicationFiled: May 13, 2013Publication date: October 2, 2014Applicant: Lifetree Biotech Co., Ltd.Inventors: Chun-Soo NA, Cheol Yi HONG, Hee Kyong KIM, Sun-Young YOON, Jin-Beom KIM, Hyun-Jung ROH, Hye-Ji NOH, Na-Na UM, Jiyoung KIM, Tae Hoon LEE
-
Patent number: 8846626Abstract: A drug composition for treating chronic liver diseases, consists of: Astragalus Astragalosides and Glycyrrhiza Acid by weight ratio of 3˜6:1. By testing and validating with classic animal model, the results confirmed that the drug composition of the present invention can significantly reduce the collagen content of rat liver, and reduce liver fibrosis and liver injury, wherein the effect is better than the effect of each component alone. The drug composition of the two components or ingredients can improve the anti-hepatic fibrosis, effectively prevent liver fibrosis and promote the development of liver fibrosis reversal, and thus can be used for the treatment and prevention of various chronic hepatitis, liver fibrosis, cirrhosis and other illnesses.Type: GrantFiled: August 26, 2011Date of Patent: September 30, 2014Assignee: Shuguang Hospital Affiliated with Shanghai University of Traditional Chinese MedicineInventor: Ping Liu
-
Publication number: 20140288015Abstract: Various methods and devices are described for affecting nerve function in the carotid body, renal nerves, and other nerves. Syringes, endovascular catheters, drug-eluting balloons, drug-eluting stents, and agent delivery patches are used to deliver a neuromodulatory agent to one or more nerves in order to treat a disease state.Type: ApplicationFiled: March 17, 2014Publication date: September 25, 2014Inventors: Kondapavulur T. VENKATESWARA-RAO, Emily A. STEIN, Michael A. EVANS, Mark H. WHOLEY
-
Publication number: 20140286931Abstract: The present invention relates to new biphenyl-3-carboxylic acid modulators of beta-3-adrenoceptor activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: June 5, 2014Publication date: September 25, 2014Inventor: Chengzhi Zhang
-
Patent number: 8841262Abstract: The present invention is directed to an agent for inhibiting peritoneal membrane thickening which enables inhibition/prevention or treatment of the peritoneal membrane thickening and which mitigates adverse effect, and a dialysis fluid comprising the aforementioned thickening inhibitory agent.Type: GrantFiled: March 30, 2010Date of Patent: September 23, 2014Assignee: CCI CorporationInventors: Hironobu Murase, Tadashi Tomo
-
Publication number: 20140274923Abstract: The present invention provides for methods of predicting progression of pediatric heart failure using miRNA biomarkers, as well as subsequent treatment of patients based on their classification.Type: ApplicationFiled: March 10, 2014Publication date: September 18, 2014Inventors: Carmen Sucharov, Brian Stauffer, Shelley Miyamoto
-
Publication number: 20140256660Abstract: The present invention describes novel single drug entities, formed by the linkage of an antibiotic with a steroidal drug via a linker. Upon topical application to the eye, the conjugate would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs.Type: ApplicationFiled: March 6, 2014Publication date: September 11, 2014Applicant: Allergan, Inc.Inventors: Santosh C. Sinha, Smita S. Bhat, Ken Chow, LIMING WANG, MICHAEL E. GARST, MAYSSA ATTAR, BRANDON D. SWIFT